Schmitz Norbert, Sureda Anna, Robinson Stephen
Department of Hematology, AK St. Georg, Hamburg, Germany.
Semin Oncol. 2004 Feb;31(1):27-32. doi: 10.1053/j.seminoncol.2003.10.018.
A number of treatment options are available for patients with relapsed Hodgkin's disease (HD). Radiotherapy, salvage chemotherapy, high-dose therapy (HDT) followed by autologous transplantation, and classical or nonmyeloablative conditioning followed by allogeneic transplantation can all be effective in patients with relapsed HD. Patients with early relapse after modern first-line chemotherapy, as well as patients with primary progressive disease, will be candidates for innovative approaches including nonmyelablative stem cell transplant (NST). Although initial results with NST look promising, more time and structured study of both HD and NST will be necessary to ultimately define the role of NST in this disease.
对于复发的霍奇金淋巴瘤(HD)患者有多种治疗选择。放射治疗、挽救性化疗、高剂量治疗(HDT)后进行自体移植,以及经典或非清髓性预处理后进行异基因移植,对复发的HD患者都可能有效。现代一线化疗后早期复发的患者,以及原发性进行性疾病患者,将是包括非清髓性干细胞移植(NST)在内的创新方法的候选者。尽管NST的初步结果看起来很有前景,但要最终确定NST在这种疾病中的作用,还需要更多时间以及对HD和NST进行更系统的研究。